Transmetalation in Cancer Pharmacology.

Area of Science:

• Metallopharmacology
• Coordination Chemistry
• Cancer Therapeutics

Background:

• Transmetalation, the exchange of metal ions, is a key mechanism in metallodrug design.
• Thiosemicarbazones (TSCs) serve as versatile ligands for metal complexation.

Purpose of the Study:

• To explore transmetalation for conditional activation of metallodrugs in cancer therapy.
• To investigate how metal ion exchange influences drug efficacy and tumor cell targeting.

Main Methods:

• Utilized thiosemicarbazones (TSCs) as a model system for transmetalation studies.
• Compared redox-active and redox-inert metal complexes (e.g., Zn(II), Ga(III), Cu(II), Fe(III/II)).
• Analyzed downstream effects including ROS generation, iron deprivation, and cell death pathways (apoptosis, ferroptosis).

Main Results:

• Redox-inert metal complexes (Zn(II), Ga(III)) were shown to convert in situ to redox-active species (Cu(II), Fe(III/II)) in acidic tumor lysosomes.
• This conditional activation localized reactive oxygen species (ROS) generation and iron deprivation to cancer cells.
• Factors like ligand tuning and metal identity were found to govern exchange kinetics and efficacy.

Conclusions:

• Transmetalation is a powerful and generalizable therapeutic principle for cancer metallopharmacology.
• Strategies like steric shielding and prodrug design can mitigate off-target effects and improve clinical translation.
• Further research is needed to quantify in-cell kinetics and optimize combination therapies.